Amarantus Bioscience Holdings Inc (AMBS)

[MagicCap]

I believe a short/quick selloff is coming when shares are transferred. This is just a guess but I think this happens and it is the last chance anyone gets to buy the stock cheap. I think people that are impatient are itching to sell the stock when they get a chance and it will give people one last chance to buy cheaply before it rockets higher.

You guys know that I'm officially about as bullish as it gets on this stock. I have been in it since $0.03 down to $0.018. I think it could dip to the $0.09 level at which point I would highly recommend to anyone not in the stock to get in. I will be using this as an opportunity to add shares.

My Thesis on Why AMBS is the Cheapest Stock in the Market

(1) Hermo Pharma is currently working on CDNF, another protein in the trophic factors family

(2) Hermo Pharma is funded by VCs and has $700k in MJFF grants

(3) World reknown Professor Mart Saarma is on the Scientific Advisory Board of Hermo Pharma:http://www.hermopharma.com/about-us/scientific-advisory-board

(4) Mart Saarma was intimately involved with GDNF and is keenly aware of the entire trophic factors family of proteins

(5) Mart Saarma has worked with Professor Steven Gill from Bristol Univ who is now leading GDNF in phase II trials. Prof Gill has developed a new infusion device that allows for much better and more efficient delivery methods: http://www.wobblywilliams.com/gdnf.html

(6) Mart Saarma and Hermo Pharma sued AMBS, challenging their patents in court in Europe on the grounds that their MANF patents cause "an undue burden on anyone trying to test MANF because it covers anything with a 90% homology (ie similarity) to MANF:"; AMBS's patents were upheld in court:
http://m.seekingalpha.com/instablog/167303-jonathan-verenger/1348791-exciting-field-in-cure-for-parkinson-s

(7) It has been shown that MANF performs better than CDNF and GDNF in pre clinical trials.

(8) GDNF was owned by a company purchased for $250 Million during pre-clinical trials.

(9) Neurturin is another trophic factor in phase I that has received $150 Million in funding.

All of the above reasons are why I'm so bullish on this company and why I think there will be much higher prices in store. I believe that a partnership/licensing deal is the most likely outcome. I don't expect a buyout. I think someone will come in initially with a $15 Million funding as well as a licensing deal. The patents that AMBS owns and that were upheld in court are far too valuable. Anyone that wants to work on MANF has to come through AMBS. If anyone alters any of the other proteins (GDNF, CDNF, etc) such that the altered protein has a 90% homology (i.e., similarity) to MANF, they have to come to MANF and license it. That is unbelievably valuable. That is why I refuse to sell this stock and why I think anyone that is not in the stock and anyone looking to flip it will come to regret it.